Literature DB >> 19206187

Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.

Hao Lu1, Kathleen England, Christopher am Ende, James J Truglio, Sylvia Luckner, B Gopal Reddy, Nicole L Marlenee, Susan E Knudson, Dennis L Knudson, Richard A Bowen, Caroline Kisker, Richard A Slayden, Peter J Tonge.   

Abstract

Francisella tularensis is a highly virulent and contagious Gram-negative intracellular bacterium that causes the disease tularemia in mammals. The high infectivity and the ability of the bacterium to survive for weeks in a cool, moist environment have raised the possibility that this organism could be exploited deliberately as a potential biological weapon. Fatty acid biosynthesis (FAS-II) is essential for bacterial viability and has been validated as a target for the discovery of novel antibacterials. The FAS-II enoyl reductase ftuFabI has been cloned and expressed, and a series of diphenyl ethers have been identified that are subnanomolar inhibitors of the enzyme with MIC90 values as low as 0.00018 microg mL(-1). The existence of a linear correlation between the Ki and MIC values strongly suggests that the antibacterial activity of the diphenyl ethers results from direct inhibition of ftuFabI within the cell. The compounds are slow-onset inhibitors of ftuFabI, and the residence time of the inhibitors on the enzyme correlates with their in vivo activity in a mouse model of tularemia infection. Significantly, the rate of breakdown of the enzyme-inhibitor complex is a better predictor of in vivo activity than the overall thermodynamic stability of the complex, a concept that has important implications for the discovery of novel chemotherapeutics that normally rely on equilibrium measurements of potency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19206187      PMCID: PMC2693246          DOI: 10.1021/cb800306y

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  44 in total

1.  Molecular basis of triclosan activity.

Authors:  C W Levy; A Roujeinikova; S Sedelnikova; P J Baker; A R Stuitje; A R Slabas; D W Rice; J B Rafferty
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

Review 2.  Biochemical mechanisms of drug action: what does it take for success?

Authors:  David C Swinney
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

Review 3.  The structural biology of type II fatty acid biosynthesis.

Authors:  Stephen W White; Jie Zheng; Yong-Mei Zhang
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

4.  In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  James A Karlowsky; Nancy M Laing; Trish Baudry; Nachum Kaplan; David Vaughan; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

5.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

Review 6.  Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Authors:  Donald T Moir
Journal:  Curr Drug Targets Infect Disord       Date:  2005-09

Review 7.  The behavior and significance of slow-binding enzyme inhibitors.

Authors:  J F Morrison; C T Walsh
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1988

8.  Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

Authors:  Christopher W am Ende; Susan E Knudson; Nina Liu; James Childs; Todd J Sullivan; Melissa Boyne; Hua Xu; Yelizaveta Gegina; Dennis L Knudson; Francis Johnson; Charles A Peloquin; Richard A Slayden; Peter J Tonge
Journal:  Bioorg Med Chem Lett       Date:  2008-04-18       Impact factor: 2.823

Review 9.  Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.

Authors:  Peter J Tonge; Caroline Kisker; Richard A Slayden
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  55 in total

1.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

2.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 3.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

Review 4.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

Authors:  Pan Pan; Peter J Tonge
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

5.  Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).

Authors:  Jiangwei Yao; John B Maxwell; Charles O Rock
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

6.  Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD(+) and triclosan.

Authors:  Shahila Mehboob; Kent Truong; Bernard D Santarsiero; Michael E Johnson
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-10-27

7.  Crystal structures and kinetic properties of enoyl-acyl carrier protein reductase I from Candidatus Liberibacter asiaticus.

Authors:  Ling Jiang; Zengqiang Gao; Yanhua Li; Shennan Wang; Yuhui Dong
Journal:  Protein Sci       Date:  2014-02-12       Impact factor: 6.725

8.  Benzoxazoles, Phthalazinones, and Arylurea-Based Compounds with IMP Dehydrogenase-Independent Antibacterial Activity against Francisella tularensis.

Authors:  Suresh Kumar Gorla; Yan Zhang; Meaghan M Rabideau; Aiping Qin; Shibin Chacko; Amanda L House; Corey R Johnson; Kavitha Mandapati; Hannah M Bernstein; Elizabeth S McKenney; Helena Boshoff; Minjia Zhang; Ian J Glomski; Joanna B Goldberg; Gregory D Cuny; Barbara J Mann; Lizbeth Hedstrom
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

9.  Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.

Authors:  Carl A Machutta; Gopal R Bommineni; Sylvia R Luckner; Kanishk Kapilashrami; Bela Ruzsicska; Carlos Simmerling; Caroline Kisker; Peter J Tonge
Journal:  J Biol Chem       Date:  2009-12-16       Impact factor: 5.157

10.  Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.

Authors:  Hao Lu; Peter J Tonge
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.